Lord, Abbett & Co. LLC Biomarin Pharmaceutical Inc Transaction History

Lord, Abbett & Co. LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$71.87 - $131.03 $5.19 Million - $9.45 Million	-72,154 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$79.55 - $124.22 $776,646 - $1.21 Million	9,763 Added 15.65%	72,154 $8.9 Million
Q1 2020 May 14, 2020	SELL	$71.37 - $96.85 $1.64 Million - $2.23 Million	-23,028 Reduced 26.96%	62,391 $5.27 Million
Q4 2019 Feb 14, 2020	SELL	$64.27 - $86.37 $2,313 - $3,109	-36 Reduced 0.04%	85,419 $7.22 Million
Q3 2019 Nov 14, 2019	BUY	$67.4 - $85.11 $471 - $595	7 Added 0.01%	85,455 $5.76 Million
Q2 2019 Aug 14, 2019	SELL	$80.35 - $93.9 $1.87 Million - $2.19 Million	-23,307 Reduced 21.43%	85,448 $7.32 Million
Q1 2019 May 15, 2019	BUY	$84.2 - $98.62 $227,845 - $266,865	2,706 Added 2.55%	108,755 $9.66 Million
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $448,703 - $593,885	-5,599 Reduced 5.01%	106,049 $9.03 Million
Q3 2018 Nov 14, 2018	BUY	$93.92 - $105.72 $119,466 - $134,475	1,272 Added 1.15%	111,648 $10.8 Million
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $3.58 Million - $4.66 Million	47,060 Added 74.33%	110,376 $10.4 Million
Q1 2018 May 15, 2018	BUY	$77.67 - $92.63 $4.92 Million - $5.86 Million	63,316 New	63,316 $5.13 Million

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.